Compare LQDA & TKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | TKC |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Turkey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.9B |
| IPO Year | 2020 | 2001 |
| Metric | LQDA | TKC |
|---|---|---|
| Price | $77.99 | $5.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $41.00 | N/A |
| AVG Volume (30 Days) | 2.1M | ★ 2.1M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.52% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $31.20 |
| Revenue Next Year | $57.13 | $24.27 |
| P/E Ratio | $148.19 | ★ $26.98 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $16.51 | $5.35 |
| 52 Week High | $82.96 | $7.18 |
| Indicator | LQDA | TKC |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 46.86 |
| Support Level | $70.28 | $5.52 |
| Resistance Level | $82.96 | $6.12 |
| Average True Range (ATR) | 4.58 | 0.10 |
| MACD | -0.89 | 0.00 |
| Stochastic Oscillator | 61.43 | 54.76 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.